- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07138027
- Original Trial
SMART Implementation-Effectiveness Trial 2 (SMART SIMPLE)
September 16, 2025 updated by: Children's Hospital of Philadelphia
Single Maintenance And Reliever Therapy Strategies for IMPLementation and Effectiveness (SMART & SIMPLE) Trial
While single maintenance and reliever therapy (SMART) has been the preferred management strategy for Step 3 and 4 (moderate/severe) asthma management since the 2020 NIH asthma guideline updates, adoption of SMART has not been rigorously assessed.
This study will test population health management (PHM; asthma community health worker, asthma nurse care manager) implementation strategies building on electronic medical record clinical decision support and education implementation strategies (CDS+), to increase adoption of SMART.
This is the second of two related records.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Asthma is a leading cause of childhood morbidity nationwide.
Limited provider adoption of and patient adherence to the prevailing evidence-based recommendations for chronic management represent tractable areas for care improvement and implementation focus.
In their 2020 Focused Updates, the NHLBI codified a new paradigm of asthma management - single maintenance and reliever therapy (SMART) - as the preferred management strategy for Steps 3 and 4 (moderate/severe) asthma management.
In addition to its efficacy and safety, SMART has demonstrated real-world effectiveness in international settings, likely due in part to better adherence to daily therapy and less inhaler confusion.
However, SMART has not been widely implemented in practice in the U.S.
This hybrid type II implementation-effectiveness study will sequentially compare the effects of usual care to (1) electronic health record-based clinical decision support plus education (CDS+) (Study 1) and then (2) CDS+ with population health management (PHM) strategies (community health worker and nurse care manager) on SMART adoption (Study 2 - current study).
Randomization for this study is at the clinic-level.
Results will be reported at visit-, patient-, and clinic-levels.
Study Type
Interventional
Enrollment (Estimated)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chén Kenyon, MD, MSHP
- Phone Number: 267-426-6339
- Email: kenyonc@chop.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Chén Kenyon, MD, MSHP
- Phone Number: 267-426-6339
- Email: kenyonc@chop.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Clinic Inclusion Criteria:
- The clinic is a pediatric primary care clinic that is part of the Children's Hospital of Philadelphia (CHOP) Pediatric Research Consortium (PeRC).
- The clinic agrees to participate in SMART & SIMPLE study.
Clinic Exclusion Criteria:
- The clinic is not willing to participate in SMART & SIMPLE study interventions.
Patient Inclusion Criteria:
- Ages 5-18 years;
- Has clinic visit at participating practice during study interval (sick, well, or follow-up)
- Prescribed at least one prescription for an inhaled corticosteroid (ICS) or ICS-long-acting beta agonist (ICS-LABA) for maintenance asthma therapy in the past year;
- Evidence of uncontrolled asthma as determined by: (1) uncontrolled Asthma Control Tool score in the past 6 months OR (2) two or more systemic corticosteroids prescribed for an asthma exacerbation in the past 12 months (one occurring in the past 6 months)
Patient Exclusion Criteria:
- Transferred clinics or left the CHOP Pediatric Care Network.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
Clinics in Arm 1 will receive the interventions in Intervals 1 and 2. Interval 1 intervention: clinical decision support and education (CDS+).
Interval 2 interventions: CDS and education (CDS+) and population health management (community health worker and nurse care manager) (PHM).
|
In Interval 1, intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+).
In Interval 2, intervention clinics will have CDS+ and population health management (PHM) strategies, including an asthma community health worker and an asthma nurse care manager.
Other Names:
|
|
Active Comparator: Control
Clinics in Arm 2 will not be exposed to the interventions.
|
Clinics in Arm 2 will not be exposed to the interventions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Rate of Visit-Level SMART Adoption
Time Frame: Assessment of rates from two study intervals: Interval 1 (CDS+; 11 months), Interval 2 (CDS+ and PHM; 11 months). There will be a one month ramp up period at the start of each study interval (ramp up period data will not be included in analyses).
|
The difference in the rate of SMART prescribing (initiation) among eligible primary care visits (i.e., when a child is eligible to start SMART) where SMART is first prescribed (initiated) comparing the second intervention period (Interval 2) and the first intervention period (Interval 1).
Adoption is visit-level.
The denominator represents eligible primary care visits, and the numerator represents visits where SMART is first prescribed (initiated).
|
Assessment of rates from two study intervals: Interval 1 (CDS+; 11 months), Interval 2 (CDS+ and PHM; 11 months). There will be a one month ramp up period at the start of each study interval (ramp up period data will not be included in analyses).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Proportion of Patient-Level SMART Sustainment
Time Frame: Assessment of proportions from two study intervals: Interval 1 (CDS+; 11 months), Interval 2 (CDS+ and PHM; 11 months). There will be a one month ramp up period at the start of each study interval (ramp up period data will not be included in analyses).
|
The difference in the proportion of patients who are prescribed (initiated) SMART who continue on SMART for at least 6 months comparing the second intervention period (Interval 2) and the first intervention period (Interval 1).
Sustainment is patient-level.
The denominator represents patients who are prescribed (initiated) SMART, and the numerator represents patients who continue on SMART for at least 6 months.
|
Assessment of proportions from two study intervals: Interval 1 (CDS+; 11 months), Interval 2 (CDS+ and PHM; 11 months). There will be a one month ramp up period at the start of each study interval (ramp up period data will not be included in analyses).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Proportion of Clinic-Level SMART Penetration
Time Frame: Assessment of proportions from two study intervals: Interval 1 (CDS+; 11 months), Interval 2 (CDS+ and PHM; 11 months). There will be a one month ramp up period at the start of each study interval (ramp up period data will not be included in analyses).
|
The difference in the clinic-level proportion of SMART-eligible patients who are prescribed (initiated) and not subsequently discontinued from SMART by the end of the interval comparing the second intervention period (Interval 2) and the first intervention period (Interval 1).
Penetration is clinic-level.
The denominator represents patients who are SMART-eligible in each interval, and the numerator represents patients who are prescribed (initiated) during the interval and still on SMART at the end of the interval.
|
Assessment of proportions from two study intervals: Interval 1 (CDS+; 11 months), Interval 2 (CDS+ and PHM; 11 months). There will be a one month ramp up period at the start of each study interval (ramp up period data will not be included in analyses).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 3, 2025
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
February 29, 2028
Study Registration Dates
First Submitted
August 15, 2025
First Submitted That Met QC Criteria
August 15, 2025
First Posted (Actual)
August 22, 2025
Study Record Updates
Last Update Posted (Estimated)
September 17, 2025
Last Update Submitted That Met QC Criteria
September 16, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Delivery of Health Care
- Health Care Quality, Access, and Evaluation
- Socioeconomic Factors
- Population Characteristics
- Technology, Industry, and Agriculture
- Technology
- Audiovisual Aids
- Educational Technology
- Television
- Videodisc Recording
- Optical Storage Devices
- Educational Status
- Compact Disks
- Population Health Management
Other Study ID Numbers
- 23-021702 B
- R01HL173600 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma in Children
-
Montefiore Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingAsthma in ChildrenUnited States
-
Meyer Children's Hospital IRCCSRecruitingAsthma in Children | Asthma Acute | Asthma Crisis | Asthma ChildhoodItaly
-
University of MiamiEnrolling by invitationAsthma in Children | Artificial IntelligenceUnited States
-
Istituto di Farmacologia Traslazionale - sede di...Not yet recruitingAsthma in Children | Children, Only | Serious Game
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)CompletedAsthma in ChildrenUnited States
-
ResMedCompletedAsthma in ChildrenUnited States
-
University of WashingtonNational Institute of Environmental Health Sciences (NIEHS); National Institute... and other collaboratorsCompleted
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruiting
Clinical Trials on Clinical decision support + education (CDS+) and population health management (PHM)
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Northwestern UniversityUniversity of California, Los Angeles; National Institute on Aging (NIA); University... and other collaboratorsActive, not recruitingPolypharmacyUnited States
-
Boston Medical CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of Colorado, DenverActive, not recruitingHeart Failure | Decision Support Systems, ClinicalUnited States
-
Vanderbilt University Medical CenterUniversity of California, San Francisco; Agency for Healthcare Research and...RecruitingPneumonia | Asthma | Lower Respiratory Tract Infection | Bronchiolitis, ViralUnited States
-
Northwestern UniversityAllianceChicago; Cook County HealthActive, not recruitingGestational Diabetes Mellitus | Hypertension in Pregnancy | DysglycemiaUnited States
-
University of Colorado, DenverCompletedHeart Failure | Decision Support Systems, ClinicalUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); Mayo Clinic; University of Alabama at... and other collaboratorsCompletedOpioid-use Disorder | Buprenorphine | Clinical Decision SupportUnited States
-
Medical University of South CarolinaNational Cancer Institute (NCI)RecruitingCancer | Surgery | Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary EmbolismUnited States
-
Inflexxion, Inc.CompletedSubstance AbuseUnited States